Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study

Abstract: Ibrutinib was approved for relapsed/refractory (R/R) mantle cell lymphoma (MCL) based on high response rates in clinical trials, but it is unclear how effective ibrutinib is in the real-world setting. This study provides population-based response rates and survival estimates and characteri...

Full description

Saved in:
Bibliographic Details
Main Authors: Trine Trab, Iman Chanchiri, Ahmed Ludvigsen Al-Mashhadi, Emma Berggren Dall, Stine Rasch, Mette Johansen, Simon Husby, Mikkel Runason Simonsen, Michael Roost Clausen, Thomas Stauffer Larsen, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Mats Jerkeman, Christian Bjørn Poulsen, Laura Mors Haunstrup, Peter Brown, Tarec Christoffer El-Galaly, Kirsten Grønbæk
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Neoplasia
Online Access:http://www.sciencedirect.com/science/article/pii/S2950328025000639
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items